Balancing GLP-1 Tolerability and Therapeutic Efficacy

Time: 8:30 am
day: Conference Day Two


  • Exploring discrepancies between efficacy and tolerability of GLP-1 mimetics
  • Highlighting how better pharmacological profiling might help enhancing tolerability of incretin mimetics based on learnings from other targets and drug classes
  • Discussing challenges and opportunities to optimize tolerability of GLP-1 therapeutic interventions